Latest @Antonisc Weekly Stock Report on eToro (26.2.2023)
Your capital is at risk. Other fees apply.
Keep up with the @Antonisc Portfolio with the Weekly Stock Report and breakdown of the current positions and expectations for the coming quarter.
Ready to start trading? Open an account now. Need more time? Try a Demo here.
Please make sure to find and follow Defensive Trading on eToro for more trading insight here.
Latest @Antonisc Weekly Stock Report on eToro (26.2.2023)
Dear @Antonisc Investors: Please find below the latest @Antonisc Weekly Stock Report on eToro (26.2.2023)
𝙊𝙐𝙍 𝙁𝙀𝘽𝙍𝙐𝘼𝙍𝙔 𝙂𝙊𝘼𝙇 𝙄𝙎 𝟲%
Current Profitability: 𝟲𝟭.𝟰𝟱%
Profitable weeks: 𝟰𝟲.𝟰𝟯%
Weekly Stock Report: What @Antonisc Like
We love $SHIBxM coin and $TONIC more than $BTC (This is not a financial advice).
NOTE: We began buying SHIB on eToro to diversify away from risk.
So far, up to November 2022 @Antonisc closed in profit the following stocks:
Part META at a profit of 24.48%, in one year all 30 closed trades were 𝟭𝟬𝟬% 𝙥𝙧𝙤𝙛𝙞𝙩𝙖𝙗𝙡𝙚.
Please also check @Antonisc’s trading history to understand when they close their positions.
Weekly Stock Report: @Antonisc
$AGNC (AGNC Investment Corp) – (STRONG BUY) – (MONTHLY DIVIDEND STOCK) – (FAIRLY VALUED)
Long term price target $11.79 – Support $11.08 – Latest total news was bearish (changed from bullish) – Sector REIT (Mortgage) – Sales growth last 12 months down – 100% (Very bad) 1-3 years sales growth forecast up 13% (Very good) To be sold at minimum profit.
APLE – (BUY) – (QUARTERLY DIVIDEND STOCK) – (FAIRLY VALUED)
Long term price target $19.00 – Support $16.66 – Latest total news was neutral – Sector REIT (Equity) – Sales growth last 12 months up 19% (Very Good) 1-3 years sales growth forecast up 26% (Excellent) To be sold at minimum profit.
ATUS – (HOLD) – (UNDERVALUED)
Long term price target $10.00 (If fundamentals improve) – Support $3.82 – Latest total news was bearish (changed from neutral) – Sector Media (Television) – Sales growth last 12 months down -6% (poor) 1-3 years sales growth forecast down -7% (Poor) To be sold at minimum profit.
CODX – (BUY) – (UNDERVALUED)
Long term price target $15.00 (If fundamentals improve) – Support $2.95 – Latest total news was neutral – Sector healthcare – Sales growth last 12 months down -83% (Very bad) 1-3 years sales growth forecast down -11% (Bad) – To be sold at minimum profit.
DELL – (STRONG BUY) – (UNDERVALUED)
Long term price target $55.00 – Support $41.51 – Latest total news was bullish (changed from bearish) – Sector computers – Sales growth last 12 months down -7% (Bad) 1-3 years sales growth forecast down -5% (Poor).
$EDU (New Oriental Education & Technology Group Inc-ADR) – (BUY) – (OVERVALUED)
Long term price target $50.00 (if fundamental improve) – Support $40.06 – Latest total news was neutral – business school – Sales growth last 12 months down -3% (Poor) 1-3 years sales growth forecast up 11% (Good) – To be sold at minimum profit.
FFIV – (HOLD) – (OVERVALUED)
Long term price target $180.00 – Support $140.06 – Latest total news was neutral – Sector Internet – Sales growth last 12 months up 2% (Good) 1-3 years sales growth forecast up 3% (Good).
$META (Meta Platforms Inc) – (STRONG BUY) – (OVERVALUED)
Long term price target $285.00 – Support $169.75 – Latest total news was neutral (changed from bullish) – Sector Internet – Sales growth last 12 months down -4% (Poor) 1-3 years sales growth forecast down -6% (Poor).
MRNA – (BUY) – (OVERVALUED)
Long term price target $302 (If fundamentals improve) – Support $135.91 – Latest news total was bearish – sector Drug – Industry Biomedical\Genetic – Sales growth last 12 months down -33% (Very bad) 1-3 years sales growth forecast down -8% (Poor) To be sold at minimum profit.
$NVAX (Novavax Inc) – (BUY) – (OVERVALUED)
Long term price target $110 – Support $9.83 – Latest news total was neutral – sector Drug – Industry Biomedical\Genetic – Sales growth last 12 months down 251% (Excellent) 1-3 years sales growth forecast up 8% (Good).
OMI – (HOLD) – (OVERVALUED)
Long term price target $22.00 – Support $20.00 – Latest news total was neutral – sector Drug – Industry Wholesale – Sales growth last 12 months up 0% (Poor) 1-3 years sales growth forecast down -5% (Poor).
$PFE (Pfizer) – (BUY) – (UNDERVALUED)
Long term price target $60.00 – Support $42.97 – Latest news total was bullish (changed from neutral) – sector Drug – Industry Wholesale – Sales growth last 12 months down -2% (Poor) 1- 3 years sales growth forecast up 14% (Very good).
PSEC – (STRONG BUY) – (MONTHLY DIVIDEND STOCK) – (FAIRLY VALUED)
Long term price target $6.50 – Support $7.58 – Latest total news was neutral – Sector Financial (Management) – Sales growth last 12 months up 38% (Excellent) 1-3 years sales growth forecast down -4% (Poor).
RH – (BUY) – (UNDERVALUED)
Long term price target $385.00 – Support $311.78 – Latest news total was bullish (changed from neutral) – sector Tech – Industry Retail – Sales growth last 12 months down -14% (Poor) 1-3 years sales growth forecast down -5% (Poor).
SWKS – (BUY) – (UNDERVALUED)
Long term price target $124.85 – Support $118.46 – Latest news total was neutral – sector Electronic – Sales growth last 12 months down -12% (Bad) 1-3 years sales growth forecast up 4% (Good).
Your capital is at risk. Other fees apply.
Next Week: @Antonisc Weekly Stock Report
𝘽𝘼𝙎𝙀𝘿 𝙊𝙉 𝘾𝙐𝙍𝙍𝙀𝙉𝙏 𝙉𝙀𝙒𝙎 𝙁𝙊𝙍 𝙊𝙐𝙍 𝘼𝘾𝙊𝙐𝙉𝙏 𝙒𝙄𝙇𝙇 𝘽𝙀 = 𝙉𝙀𝙐𝙏𝙍𝘼𝙇
Please do not copy us if you expect to make millions in one go, our investments are long term and could hold them for up to 3-7 months if necessary. We don’t use leverage therefore you will have no daily fees when investing in us, rather you might get dividend payouts due to our long-term hold in some stocks. Also, we advise our short term investors to invest in us when we have a red month and sell us when we have a strong green. Our long-term investors should just hold until they retired.
Read our related post: How to Copy Trade on eToro.
The Pros and Cons of CopyTrading on eToro
eToro Copy Trading Pros
✅ eToro supports thousands of stocks and ETFs listed on such stock exchanges as NASDAQ, NYSE, etc.
✅ Not only US companies but also companies based in Germany, France, the UK, Canada, Spain, and several other countries, are listed on eToro.
✅ The platform is extremely versatile and you can buy multiple other assets along with stocks, including cryptocurrencies, forex, commodities, and indices which are also available through contracts for differences.
✅ The broker offers a competitive pricing structure – you can buy stocks with zero commissions and spreads are below market rates.
✅ eToro supports a social trading platform where users can have discussions with other traders, ask questions to experts and follow the news.
✅ eToro offers other free social trading tools in addition to CopyTrader and CopyPortfolios which can be used to mirror the trades of any trader with a click of a button.
✅ The broker is very safe and uses top-notch safety mechanisms to protect your account from fraud and malicious logins.
✅ eToro is a highly regulated platform and is registered with such reputable institutions as ASIC in Australia, CySEC in Cyprus, FCA in the UK, and FinCEN in the United States.
✅ The platform is very beginner-friendly: it has a simple-to-use interface and educational content for newbies.
✅ eToro supports multiple payment methods – credit and debit cards, bank transfers, rapid transfers, Neteller, Skrill, etc.
eToro Copy Trading Cons
❌ The platform is not available in many US states.
❌ Customer service by the Copy Trader is not guaranteed.
❌ The broker does not impose minimum level requirements for CopyTraders.
❌ The charting software is limiting on the platform, however, this can be overcome by using the advanced charting options at Trading View.
Your capital is at risk. Other fees apply.
